Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes

被引：0
|
作者：
Rizzo, A. [1 ]
Rinaldi, L. [1 ]
Massafra, R. [1 ]
Cusmai, A. [1 ]
Guven, D. C. [2 ]
La Forgia, D. [1 ]
Latorre, A. [1 ]
Giotta, F. [1 ]
机构：
[1] Ist Tumori Bari Giovanni Paolo II IRCCS, Oncol Inst, Bari, Italy
[2] Hacettepe Univ, Dept Med Oncol, Oncol Hosp, Ankara, Turkiye
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412P
引用
收藏
页码：S356 / S356
页数：1
相关论文
共 50 条
  • [11] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [12] Real-world outcomes of sacituzumab govitecan in breast cancer
    Singh, Vaishnavi
    Dhaibar, Hemangini
    Peddi, Prakash
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [13] Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial
    Ergun, Yakup
    LANCET, 2024, 404 (10450): : 337 - 338
  • [14] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Xie, Jiao
    Li, SiNi
    Li, YaMin
    Li, JianHe
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [15] Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer
    Sg, Nithin
    Gogia, Ajay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08)
  • [16] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [17] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Jiao Xie
    SiNi Li
    YaMin Li
    JianHe Li
    BMC Health Services Research, 23
  • [18] Efficacy and safety of sacituzumab govitecan in HR+/HER2-advanced breast cancer: A comprehensive systematic review and meta-analysis
    Qureshi, Zaheer
    Jamil, Abdur
    Altaf, Faryal
    Siddique, Rimsha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [19] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024,
  • [20] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Bardia, A.
    Tolaney, S. M.
    Punie, K.
    Loirat, D.
    Oliveira, M.
    Kalinsky, K.
    Zelnak, A.
    Aftimos, P.
    Dalenc, F.
    Sardesai, S.
    Hamilton, E.
    Sharma, P.
    Recalde, S.
    Gil, E. C.
    Traina, T.
    O'Shaughnessy, J.
    Cortes, J.
    Tsai, M.
    Vahdat, L.
    Dieras, V
    Carey, L. A.
    Rugo, H. S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1148 - 1156
12345